"Indian Pharmaceutical Industry: Has It Gone Off Track? Didn’t Use Its Resources, Govt Funding & Manpower Properly"- By Dr Madhuresh Kumar Sethi

Introduction

The Indian pharmaceutical industry has long been regarded as a global healthcare partner — a powerhouse in generics and vaccines, and a lifeline for affordable medicine across continents. Yet, as the global pharma landscape rapidly evolves toward innovation, biologics, and precision medicine, questions are being raised about whether India has fully capitalized on its internal strengths.

Despite a favorable ecosystem — a large scientific workforce, policy support, and global trust — the industry appears to have underleveraged its capabilities in R&D, policy implementation, and talent development. The concern is not about decline but about missed opportunity. Has the sector veered off course by focusing too narrowly on volume-led exports while underinvesting in innovation and infrastructure?

1. Strong Foundations, But a Narrow Base

India's pharma rise post-2005, following TRIPS compliance, was swift and strategic. With over 8,000 drug manufacturers, the country became synonymous with cost-effective generics and vaccines, currently contributing:

• ~60% of global vaccine demand
• ~20% of global generics exports

However, this growth has largely come from reverse engineering and low-margin generics, while other nations advanced in biosimilars, novel therapies, and AI-led drug discovery. India’s comparative advantage has been cost — not innovation.

This poses a risk: as regulatory expectations rise and innovation-driven therapies dominate, India’s position in the value chain may stagnate.

2. R&D Investment: The Weakest Link

For a sector of such scale, India’s R&D spending — under 8% of revenue on average — is notably low. Most firms prioritize abbreviated new drug applications (ANDAs) for regulated markets over novel drug development. Several underlying issues persist:

• Fragmented research ecosystems
• Weak industry-academia collaboration
• Limited appetite for long-gestation R&D investments

Government initiatives like the Pharma Innovation Programme 2020 and the PLI Scheme for R&D show policy-level intent. However, their impact remains constrained by complex approval processes, insufficient institutional accountability, and minimal industry uptake.

Without consistent, mission-driven innovation funding and infrastructure, India risks lagging behind emerging biotech ecosystems globally.

3. Government Support: Ambitious on Paper, Patchy in Practice

Government interventions have targeted critical challenges — from dependency on Chinese APIs to export competitiveness and drug security. Yet, implementation gaps limit their effectiveness.

Key concerns include:

• Delayed infrastructure development in bulk drug parks
• Inadequate coordination across central and state bodies
• Under-disbursed funds under incentive schemes
• Limited transparency in scheme eligibility and evaluation

Moreover, while countries like China have pursued centrally coordinated pharma strategies, India’s policy landscape remains fragmented, with overlapping regulatory jurisdictions and disjointed execution models.

4. Manpower: Quantity Without Alignment

India's pharmaceutical education system produces more than 150,000 graduates annually, yet employers continue to face skill shortages. The disconnect lies in:

• Outdated curricula with limited relevance to industry needs
• Poor exposure to GMP, regulatory science, and digital tools
• Limited availability of trained talent in niche areas like pharmacovigilance, clinical research, and biologics manufacturing

The result is a paradox: an oversupply of graduates, but a deficit of job-ready professionals. Unless academia and industry collaborate to design relevant, applied programs, India’s demographic dividend will remain underutilized.

5. Regulatory Compliance: An Area of Repeated Concern

Despite being a leading exporter to the US and EU, Indian pharma companies continue to face challenges related to regulatory compliance. Between 2015 and 2023, several firms received FDA warning letters, import alerts, and inspection failures due to:

• Data integrity lapses
• Poor documentation practices
• Insufficient quality control mechanisms

These issues point to systemic weaknesses rather than isolated errors. They threaten the credibility India has built over decades and risk reducing long-term trust with global regulatory agencies.

A robust, transparent, and quality-driven compliance culture must become central — not peripheral — to the industry’s strategy.

6. Innovation Culture: Still Nascent

India has produced a few R&D-led success stories — notably in biosimilars and vaccines — but they remain exceptions. Several structural and mindset barriers prevent the growth of an innovation-first ecosystem:

• Weak IP enforcement and monetization frameworks
• High cost and time cycles of new drug discovery
• Absence of venture capital for deep-science startups
• A bias toward short-term returns over long-term value creation

To change this, India needs to promote high-risk, high-reward R&D, incentivize collaborative research, and build national innovation clusters around translational medicine, biotech, and digital therapeutics.

7. A Path Forward: From Reactive to Strategic

The Indian pharmaceutical industry is not in crisis — but it is in a critical phase of transition. To remain globally competitive and strategically relevant, the sector must undergo a thoughtful realignment.

Key priorities should include:

• Execution-centric policy governance: Simplify schemes, ensure timely disbursals, and build accountability metrics across central and state authorities.
• Industry-ready talent development: Partner with institutions to design real-world, skills-based programs aligned with evolving pharma roles.
• Integrated innovation ecosystems: Encourage co-development, contract research partnerships, and early-stage biotech funding mechanisms.
• Global quality leadership: Move beyond minimum regulatory thresholds and aim to be recognized as a benchmark for quality and ethics.
• Digital and data adoption: Embrace automation, AI-led R&D, and smart manufacturing to boost competitiveness and compliance.

Conclusion

The Indian pharmaceutical industry has built a global reputation through decades of disciplined growth, scale, and cost efficiency. However, the future will not be shaped by volume alone. It will be defined by the ability to innovate, the capacity to ensure quality, and the foresight to build systems that last.

The sector must now move from being a back-office to the global pharma supply chain to becoming a front-runner in global healthcare innovation. The resources, policy support, and manpower exist — but their potential remains largely untapped.

The question isn’t whether the Indian pharmaceutical industry has gone off track. The question is whether it can now realign — with urgency, clarity, and ambition.